Drug Trial Radar · NCT02859857
Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Jul 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
86
Actual
Start
Sep 1, 2016
Primary completion
Jun 17, 2019
Study completion Jun 15, 2020
Sponsor
- Lead sponsor
- Bexion Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- CTI Clinical Trial and Consulting Services
- First posted
- Aug 9, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to characterize the safety profile and determine the maximum tolerate dose (MTD) of BXQ-350, when given as a single agent at escalating doses, according to the investigational product (IP) related dose-limiting toxicities (DLTs) in patients with advanced solid tumors. Secondarily to assess the preliminary antitumor activity of BXQ-350 in solid tumors and recurrent high grade gliomas.
Conditions
- Neoplasms
Interventions
BXQ-350Drug
BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes. When both the components are assembled together stable SapC-DOPS nanovesicles are formed(clinical formulation BXQ-350).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1-MTDTime frame: 12 months
- Part 2-RECISTTime frame: 12 months
- Part 2-RANOTime frame: 12 months
- Part 3 - RECISTTime frame: 12 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
University of Kentucky Markey Cancer Center
Lexington, Kentucky
University of New Mexico Cancer Center
Albuquerque, New Mexico
University of Cincinnati Barrett Center
Cincinnati, Ohio
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.